NewsSource: EClinCloud

EClinCloud Product Overview | eCOA · Electronic Clinical Outcome Assessment System

1 min readEClinCloud Editorial Team
News header image for EClinCloud Product Overview | eCOA · Electronic Clinical Outcome Assessment System

Source: EClinCloud. Author: EClinCloud.


EClinCloud eCOA (electronic Clinical Outcome Assessment) is the digital version of clinical outcome assessment (COA). Through mobile and PC integration, it collects comprehensive trial data across five dimensions: ePRO (electronic patient-reported outcome), eClinRO (electronic clinician-reported outcome), eObsRO (electronic observer-reported outcome), ePerfO (electronic performance outcome), and eDiary (electronic diary).


computer-ai.png

AI-Driven One-Stop Product + Service Solution


🔍 What Can EClinCloud Provide?

◉ Scale management and consulting services

◉ Rater training services

◉ Electronic study system build services

◉ System training and quality control support services



💻 Features of the EClinCloud eCOA System




◉ Multidimensional alert rules to help users conduct proactive data quality control

◉ Comprehensive two-way reminders so both participants and study personnel receive notifications

◉ Full-workflow data quality management operations, meeting the prerequisites for data-silo operation

◉ Powered by independently trained AI models to assist users in implementing unified SOP standards



💡 Why Choose EClinCloud eCOA?


❖ Clean, efficient system with comprehensive functional support and no extra data-entry burden

❖ Complete, robust closed-loop data workflow

❖ Dedicated software and hardware solution team with full-lifecycle service tracking

❖ Reuse of successful inspection experience across multi-indication studies

❖ Reuse of successful international study experience






About EClinCloud


EClinCloud is a leading AI company in the clinical research industry. Driven by AI, it builds an integrated clinical intelligence cloud platform and endpoint assessment technologies to provide global pharmaceutical companies and research institutions with technology products—including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM—along with scale management, linguistic validation, rater training, and data quality analysis services, creating efficient and precise digital solutions. Leveraging AI predictive models and its intelligent data platform, EClinCloud dynamically evaluates and helps improve drug clinical trial success rates, helping shorten drug and device R&D cycles to benefit patients.







Article image




Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.